KAZIA THERAPEUTICS LTD (KZIA) Form 6-K — Aug 27, 2026
Kazia Therapeutics reported that its lead asset paxalisib achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer in its Phase 1b trial combining paxalisib with pembrolizumab and chemotherapy. Five of six patients achieved an objective response (one complete, four partial) for an 83% response rate, with no paxalisib-related serious adverse events. Translational data showed all six patients experienced a median 83% reduction in metastasis-associated circulating tumor cell clusters and a median 51% reduction in terminally exhausted CD8+ T cells.
Key figures
- Total Debt
- 0
- Cash Position
- Approximately US$46 million (as of 12/31/25)
- Shares Outstanding
- Approximately 14.1 million American Depository Shares (fully diluted)
- Cash Runway
- Expected to fund planned operations into 2029
- Paxalisib Doses
- 15mg and 30mg once daily
- Clinical Benefit Rate
- 100% (6/6 evaluable Stage IV TNBC patients)
- Objective Response Rate
- 83% (5/6 patients: 1 complete response, 4 partial responses)
- Stable Disease Patients
- 1
- Phase1b Planned Enrollment
- 36
- Ctc Cluster Reduction Median
- 83% (range 76-90%) within 6-7 weeks
- Paxalisib Patent Protection
- Projected until 2043, coverage in over 40 jurisdictions
- Potential Market Opportunity
- >$40B (TNBC ~$6B, HR+/HER2- breast cancer ~$17B, pMMR CRC ~$18B by 2030)
- Enrollment Completion Expected
- July 2027
- Exhausted TCell Reduction Median
- 51% (range 18-97%) within ~3 weeks
- Patients Treated With Paxalisib To Date
- >550 across Phase 1-3 trials and expanded access
- Metastatic TNBCFive Year Survival Historical
- 12%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.